Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2021) 73 OC8.5 | DOI: 10.1530/endoabs.73.OC8.5

1Mugla Sitki Kocman University Faculty of Medicine, Department of Internal Medicine, Turkey; 2Mugla Sitki Kocman University Faculty of Medicine, Department of Endocrinology and Metabolism, Turkey; 3Mugla Sitki Kocman University Faculty of Medicine, Department of Medical Biology, Turkey; 4Pamukkale University Faculty of Medicine, Department of Endocrinology and Metabolism, Turkey; 5Zonguldak Bulent Ecevit University Faculty of Medicine, Department of Medical Biology, Turkey; 6Fırat University Faculty of Medicine, Department of Medical Biology, Turkey


Background and aim

MicroRNAs (miRNA) are small nucleotide sequences that affect gene expression in cells at the posttranscriptional level. Some miRNAs behave like oncogenes, while others behave like tumor suppressors. In this study, it was aimed to investigate the role of miRNAs in tumor development and its effects on clinical and metabolic parameters of the patients with acromegaly.

Methods

39 patients diagnosed with acromegaly (20 F / 19 M, mean age 51.6 ± 10.1 years) and 39 age–and gender-matched healthy controls (27 F/ 12 M, mean age 52.1 ± 12 years) were included in the study. The levels of miR-16, miR-26a, let-7, miR-128a and miR-223 were measured in peripheral blood by real-time PCR methods. Demographic features of the patients, radiological features of the adenoma, treatment modalities and comorbidities of the patients were evaluated. The relationship between these parameters and miRNAs was evaluated.

Results

While there was no significant difference in miR-16, miR-26a and miR-128a levels between acromegalic patients and the control group, let-7 levels were found to be lower in acromegalics compared to the control group [0.945 (0.29–5.77) vs1.261 (0.25–3.1); P = 0.053]. Moreover, acromegalic patients had significantly higher miR-223 levels compared to controls [2.101 (0.004–7.56) vs1.52 (0.36–10.22); P = 0.021]. There was no effect of miRNAs on adenoma size, optic chiasm compression and cavernous sinus invasion of the adenoma. Regarding the effects of miRNAs on need of medical treatment, miR-26a expression is demonstrated to be increased in patients who use medical treatment (N: 26, 66.6%) [1.22 (0.63–5.98) vs 0.74 (0.51–2.62); P = 0.004] whereas miR-16, let-7, miR-128a and miR-223 levels were found to be similar in both groups. When the patients were evaluated according to the presence of of coronary artery disease, hypertension, hyperlipidemia, Type 2 diabetes mellitus, malignancy and colonic polyps, no statistically significant difference was found between the groups in all miRNA levels.

Conclusion

Decreased expression of tumor suppressor gene let-7 miRNA levels and increased expression of oncogene miR-223 levels suggest that these two microRNAs may have a role in tumor development in acromegaly. While these was no effect of these miRNAs on the development of clinical features and comorbidities of acromegalic patients, increased miR-26a expression in patients receiving medical therapy supports the potential role of miR-26a in determining the long-term prognosis of acromegalic patients.

Volume 73

European Congress of Endocrinology 2021

Online
22 May 2021 - 26 May 2021

European Society of Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.